CAR-T细胞治疗对比历史对照在复发/难治侵袭性B细胞淋巴瘤中的真实世界疗效
该研究基于加拿大安大略省人群的回顾性队列,比较2019-2023年接受公共资助CAR-T治疗的患者与2013-2018年历史对照的生存结局。共纳入314例CAR-T患者和106例历史对照,中位随访29.6个月,CAR-T组中位总生存15.1个月,历史对照4.8个月,风险比0.50(95%CI 0.38-0.65)。结果支持CAR-T在常规临床中改善复发/难治侵袭性B细胞淋巴瘤的生存。
要点
- 真实世界中CAR-T组中位OS为15.1个月,历史对照为4.8个月,HR 0.50。
- 研究采用IPTW平衡两组基线特征,支持CAR-T的生存获益。
- 中位随访29.6个月,结果来自加拿大安大略省公共资助项目。
核心结论
- 在真实世界常规诊疗中,CAR-T细胞治疗较历史对照显著改善复发/难治侵袭性B细胞淋巴瘤患者的总生存。
研究设计与样本
- 基于加拿大安大略省的人群回顾性队列研究,纳入2013年1月至2023年6月治疗的患者。
- 共纳入314例CAR-T患者和106例历史对照,采用逆概率治疗加权(IPTW)平衡两组特征。
主要发现
- 中位随访时间为29.6个月(95%CI 26.1-33.0)。
- CAR-T组中位总生存为15.1个月(95%CI 11.1-26.3),历史对照组为4.8个月(95%CI 3.8-6.4)。
- CAR-T组对比历史对照的风险比为0.50(95%CI 0.38-0.65)。
临床怎么用
- 结果支持在常规临床实践中对复发/难治侵袭性B细胞淋巴瘤患者使用公共资助的CAR-T细胞治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Single-arm studies demonstrate dramatic improvements in survival in patients with relapsed/refractory (R/R) aggressive B-cell lymphomas but with significant toxicities and at exceptionally high costs. The objective of this study was to evaluate the real-world health outcomes of aggressive B-cell lymphoma patients treated with publicly funded chimeric antigen receptor (CAR) T-cell therapy in Ontario, Canada, compared to historical controls. We conducted a population-based retrospective cohort study among patients treated for R/R aggressive B-cell lymphoma in Ontario between January 2013 and June 2023. The cohort consisted of patients who received commercially available CAR T cells between 1 January 2019 and 30 June 2023 and historical controls who were treated with the standard of care between 1 January 2013 and 31 December 2018, before public funding for CAR T-cell treatments was available. Inverse probability of treatment weighting (IPTW) was used to balance patients' characteristics across the two groups. The cohort included 314 CAR T-cell patients and 106 historical controls. The median follow-up time was 29.6 months (95% confidence interval [CI]: 26.1-33.0), and the median overall survival was 15.1 months (95% CI, 11.1-26.3) and 4.8 months (95% CI, 3.8-6.4) for CAR T-cell-treated patients and historical controls (hazard ratio 0.50, 95% CI 0.38-0.65) respectively. These results support the benefit of CAR T-cell treatment for patients with R/R aggressive B-cell lymphoma in routine clinical care.
引用
- Villeneuve PJA, Mozessohn L, Somé NH, et al. Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting. Br J Haematol. 2026. PMID: 42410301. doi:10.1111/bjh.70632
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。